The Fly

Charles River could be hurt by NHP supply challenges in FY23, says BofA

BofA analyst Derik de Bruin maintains a Buy rating and $260 price target on shares of Charles River Laboratories, telling investors in a research note that the company’s 8-K and management comments highlight supply uncertainty for nonhuman primate animal models. Charles River does not see this issue hurting its FY22 outlook, but management noted that it’s still too early to comment on the nature of the potential headwind in FY23, the analyst says, adding that he thinks it is likely that the drug industry and regulators would opt to substitute other animal models rather than slow the development of new drugs.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CRL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More